Skip to Content

New Drug Approvals Archive - December 2016

See also: New Indications and Dosage Forms for December 2016

December 2016

Eucrisa (crisaborole) Topical Ointment

Date of Approval: December 14, 2016
Company: Pfizer, Inc.
Treatment for: Atopic Dermatitis

Eucrisa (crisaborole) is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Rubraca (rucaparib) Tablets

Date of Approval: December 19, 2016
Company: Clovis Oncology, Inc.
Treatment for: Ovarian Cancer, Prostate Cancer

Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer and prostate cancer.

Spinraza (nusinersen) Injection

Date of Approval: December 23, 2016
Company: Biogen
Treatment for: Spinal Muscular Atrophy

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.